

Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH

Julia Kirchheiner · Silke Glatt · Uwe Fuhr ·
Ulrich Klotz · Ingolf Meineke · Thomas Seufferlein ·
Jürgen Brockmüller

Received: 23 June 2008 / Accepted: 22 September 2008 / Published online: 17 October 2008
© Springer-Verlag 2008

Abstract

Aim Comparative potency of proton-pump inhibitors (PPIs) is an important clinical issue. Most available trials have compared the different PPIs at one or a few selected specific dosages, making it difficult to derive quantitative equivalence dosages. Here we derived PPI dose equivalents based on a comprehensive assessment of dose-dependent effects on intragastric pH.

Methods All available clinical studies reporting the effects of PPIs on mean 24-h intragastric pH were sought from electronic databases including Medline. Studies included

were restricted to those targeting the Caucasian population, and healthy volunteers or gastroesophageal reflux disease (GERD) patients. The dose-effect relationships for mean 24-h intragastric pH and for percentage of time with pH > 4 in 24 h were analyzed for each PPI using pharmacodynamic modeling with NONMEM and a model integrating all available data.

Results Fifty-seven studies fulfilled the inclusion criteria. Based on the mean 24-h gastric pH, the relative potencies of the five PPIs compared to omeprazole were 0.23, 0.90, 1.00, 1.60, and 1.82 for pantoprazole, lansoprazole, omeprazole, esomeprazole, and rabeprazole, respectively. Compared with healthy volunteers, patients with GERD needed a 1.9-fold higher dose and *Helicobacter pylori*-positive individuals needed only about 20% of the dose to achieve a given increase in mean 24-h intragastric pH.

Conclusion The present meta-analysis provides quantitative estimates on clinical potency of individual PPIs that may be helpful when switching between PPIs and for assessing the cost-effectiveness of specific PPIs. However, our estimates must be viewed with caution because only a limited dose range has been tested and not exactly the same study conditions were applied for the different substances.

J. Kirchheiner (✉) · S. Glatt
Institute of Pharmacology of Natural Products and Clinical
Pharmacology, University of Ulm,
Helmholtzstr. 20,
89081 Ulm, Germany
e-mail: julia.kirchheiner@uni-ulm.de

U. Fuhr
Department of Pharmacology, Clinical Pharmacology,
University of Cologne,
Cologne, Germany

U. Klotz
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology,
Stuttgart, Germany

T. Seufferlein
Department of Internal Medicine I, University of Halle,
Halle, Germany

I. Meineke · J. Brockmüller
Department of Clinical Pharmacology,
Georg August University Göttingen,
Göttingen, Germany

Keywords Proton-pump inhibitor · PPI · Gastric pH ·
Acid suppression · Omeprazole · Lansoprazole ·
Pantoprazole · Rabeprazole

Introduction

Proton-pump inhibitors (PPIs) are the most effective drugs in current treatment of acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and

gastric or duodenal ulcer with and without *Helicobacter pylori* infections. At present, there are five different substances on the market that have been extensively studied in numerous comparative clinical trials [1–3]. Data from meta-analyses indicate little difference in cure rates of acid-related diseases (i.e., GERD) at the approved doses of PPIs. Also *H. pylori* eradication rates did not differ very much among different PPIs, indicating similar efficacy with different doses reflecting differences in potency [4, 5].

For the majority of the population, the currently used PPI doses may be in the flat plateau part of the dose response curve, and therefore from comparative trials with clinical endpoints, no precise estimates on relative potency of the PPIs can be deduced. To our knowledge, no generally accepted tables or guidelines about equipotent PPI dosages have been developed. In clinical practice, however, knowledge of the dose needed to obtain a certain effect in a patient is very important. Such information would also provide the rationale for dose selection when replacing one PPI by another, which is often desired as hospital formularies may be limited to a single PPI. In addition, in spite of the generally high efficacy, there are numerous poor responders to PPI treatment, and in such patients, one might wish to switch between different substances and would like to know the relative potencies more precisely. Finally, it may be relevant to know what PPI potency can be obtained at what price. Due to the high prevalence of acid-related disorders this question is of major pharmacoeconomic impact.

Pharmacodynamic effects of PPIs can be assessed in different ways. One common parameter is the continuous measurement of the intragastric pH over 24 h. In patients with GERD, especially patients not responding to usual therapies, esophageal and gastric pH monitoring is a useful technique to assess compliance, pH control, and to investigate the association of reflux with therapy-refractory symptoms [6]. Intragastric pH monitoring in healthy individuals allows direct assessment of acid suppression achieved with an agent and is useful for head-to-head comparisons of antisecretory therapies, but it also may be helpful to guide clinicians in dose titration and in evaluating the effect when switching agents. In clinical trials, acid suppression is typically assessed and summarized as the mean pH over a defined time interval or as the percentage of time during which the pH is above 4 (used as surrogate parameter for the healing of GERD) or above 3 (used as surrogate parameter for the healing of peptic ulcer) [7–9].

When evaluating variability in individual gastric pH response, factors such as dose timing and food effect, as well as pharmacogenetic factors play a role [10, 11]. Differences in intragastric pH have been described between *Helicobacter pylori* (Hp)-positive and Hp-negative individ-

uals, with higher mean pH values and better efficacy of PPIs in Hp-positive individuals [12–14]. There also might be differences in gastric pH values among patients with GERD since gastric acid production is significantly higher in GERD patients than in non-GERD patients due to differences in nocturnal acid production [15]. Finally, the *CYP2C19* genotype has been shown to have substantial effects on PPI exposure with higher plasma concentrations and better acid suppression in poor metabolizers [16]. This, however, is epidemiologically more relevant in Asian countries where the frequency of the *CYP2C19* poor metabolizer genotype is about 20% compared to only about 3% in Caucasians [17]. Optimally, the individual *CYP2C19* genotype should be available for the comparison, but most studies did not provide this data.

For all the reasons given above, a comparative analysis has to consider the underlying disease, and potency of PPIs can only be compared within a given group (healthy volunteers, ulcer patients, GERD patients) and within one ethnic group (Africans, Asians, or Caucasians). In this systematic analysis, we evaluated all available clinical studies measuring effects on gastric pH in relation to drug and dose in order to generate information on clinically comparative dosages. Specifically, we derived equivalent dosages of PPIs from the mean 24-h pH and from the percent of time with pH>4, taking the diagnosis of study participants into account.

Methods

Data search and selection

A systematic search in Medline (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi>) was performed using the international nonproprietary names of PPIs (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole) in combination with key terms “intragastric,” “gastric,” “pH,” “acid suppression,” “mean pH,” “intragastric acidity,” “acid secretion,” “24-hour.” In addition, we manually searched the bibliographies of key original or review articles for references not captured by the systematic keyword search strategy. Since we found few data beyond that, we decided not to include articles from non-peer-reviewed journals, data published only on the manufacturer’s websites or given in the drug labeling, conference abstracts, or studies available only on the webpage of the U.S. Food and Drug Administration (FDA) (<http://www.fda.gov/cder/approval/index.htm>).

Two independent reviewers extracted the information from the relevant articles into a database. Data were taken from the text, tables, and figures. All clinical studies published through January 2007 in patients with GERD or

in healthy volunteers with intragastric 24-h pH monitoring were included. We restricted the patient studies to those with GERD because very few studies with 24-h pH assessment were available for other diseases such as peptic ulcer or Zollinger-Elison syndrome. Studies performed exclusively in Hp-positive healthy volunteers or patients were analyzed separately [12, 13]. Finally, included studies were limited to those performed in Caucasians since there are substantial interethnic differences influencing the relationship between dose and effects on intragastric pH between Caucasian and Asian populations such as frequency of the *CYP2C19* metabolic genotype, which is relevant for all PPIs, other genetic differences, mean body mass index, and epidemiology of diseases [17, 18]. Thus, data obtained in Asian populations must be analyzed and published separately and may even result in a different ranking of the relative potencies of the PPIs compared to Caucasian populations due to a differential impact of the *CYP2C19* genotype for the different PPIs.

Finally, we only included data obtained with standard solid oral formulations (tablets or capsules). All doses provided in this review refer to the dosing information as given by the manufacturer. Since rabeprazole doses refer to rabeprazole sodium, which contains 94.2% pure rabeprazole as the active pharmaceutical ingredient (API), whereas all other PPIs doses refer to the pure base equivalent to 100% API, the true rabeprazole dose is 94% of the dose given in the drug description.

The aim was to gather data on as many drug dosages as possible. Therefore, relatively broad inclusion criteria were chosen. Since only the dose-effect relationship was analyzed, we did not restrict the search to randomized controlled trials only. In particular, phase I trials on intragastric pH in healthy volunteers were conducted without a comparison group and were included. If trials contained different study arms, the arms relevant for our analysis were included, if possible.

Data analysis

The following parameters were taken from each study when available: identity and dosage of PPI, sample size, mean 24-h intragastric pH, and percentage of time with pH>4 in 24 h. When available, mean values for the effect parameters and the respective parametric measurements of variability (standard deviation, standard error of the mean, or confidence interval) were extracted. Standard errors of the mean and confidence intervals were transformed to standard deviation for subsequent calculations. In some studies, only median and nonparametric variability parameters such as range or interquartile range were given. In this case, we included the median instead of the mean but we did not include the nonparametric variability parameters.

For studies with the same PPI and dosage, overall means weighted by sample size were calculated for the effect parameters as described in Eq. 1:

$$\bar{X} = \frac{\sum_{j=1}^M n_j \bar{x}_j}{N} \tag{1}$$

with \bar{X} being the overall mean, M the number of studies, N the overall number of subjects, n_j the number of subjects in the individual study and \bar{x}_j the means of the individual studies. The overall variance S^2 was calculated from the individual study means \bar{x}_j , the individual sample size per study n , and the individual standard deviations of the studies (Eq. 2):

$$S^2 = \frac{\left(\sum_{j=1}^M \sum_{i=1}^n s^2 \cdot (n-1) + n \cdot \bar{x}^2 \right) - N \cdot \bar{X}^2}{N-1} \tag{2}$$

with i representing the individual subjects in the studies, j representing the individual studies, M the number of studies, N the sum of the sample size of all studies and \bar{X} the overall mean calculated as weighted mean as described above. Overall standard deviation was calculated as the square root of that variance.

Studies on intragastric pH after a single dose of a PPI were analyzed separately from studies in which pH measurement was performed under steady-state conditions after several days of administration of the same dose. Data for patients with GERD were analyzed separately from data in healthy volunteers. Studies that did not test for Hp status, studies with the average percentage of Hp-positive individuals in the population, and studies excluding Hp-positive individuals were grouped together for analysis. In contrast, studies including only Hp-positive individuals were analyzed separately.

Estimation of equivalence dosages

All available data concerning 24-h pH (125 different groups with sample sizes between 4 and 65 with a total of 2,738 patients) were analyzed in one integrated model using NONMEM V version 1.1. The individual studies were weighted according to their sample size. The 24-h pH obtained during steady-state treatment with the respective PPI was analyzed in dependence of dose according to an E_{max} model with baseline pH (pH_{basal}) as follows:

$$pH = pH_{basal} + \frac{E_{max} \times dose}{ED_{50} + dose}$$

or to calculate the doses required to achieve specific 24-h pH values:

$$\text{dose} = \frac{\text{ED}_{50}}{\frac{E_{\max}}{\text{pH} - \text{pH}_{\text{basal}}} - 1}$$

E_{\max} is the maximum achievable increase in gastric pH above the baseline value measured prior to treatment. ED_{50} is the dose required to obtain half-maximum increase in pH and is modeled with a variance parameter reflecting inter-disease variability (IIV) in an exponential error model. By including this parameter (IIV) for interindividual variation, differences among the three health-condition groups (healthy volunteers, Hp-infected patients, GERD patients) were described. Differences in potency of the PPIs were included in the final model as a factor (K) with lansoprazole as the reference since the most detailed data were available for this PPI. Therefore, K was arbitrarily set to unity for this drug. Thus, with TVED_{50} as the overall population estimate of the dose to achieve maximum increase in pH, in the final model it was $\text{ED}_{50} = (\text{TVED}_{50} \pm \text{IIV}) \times K$.

The potency factors were calculated by dividing the ED_{50} of omeprazole by the ED_{50} of each PPI. They were calculated for the parameters “mean 24-h pH” and “percentage of time $\text{pH} > 4$.” The absolute equivalence doses were calculated compared to omeprazole 20 mg dose by dividing by the potency factor.

Statistical testing

Differences among GERD patients, healthy volunteers, and Hp-positive volunteers as well as between single and multiple doses were analyzed using univariate analysis of variance (ANOVA) with study, treatment (single dose/multiple dose), and disease status (GERD or healthy) as factors and either 24-h pH or percent time $\text{pH} > 4$ as dependent variables. Statistical significance of two-group comparisons was assessed by the Student's *t*-test.

Results

A total of 304 publications of potentially relevant clinical trials were obtained from which 151 citations were retrieved for further analysis. Trials using intravenous administration of the drugs, studies in patients with diseases potentially influencing gastric pH, and studies that did not perform 24 h of gastric pH measurement were excluded resulting in 57 clinical studies included in the analysis (Fig. 1). Forty-three of the studies were performed in healthy individuals, 12 in GERD patients, and 2 studies were performed exclusively in Hp-positive healthy individuals [19, 20]. Testing for Hp




Fig. 1 Flow diagram on inclusion and exclusion of trials (randomized controlled trials, RCTs). Adapted from the Quorum statement flow diagram [93]

was performed in 36 of 57 studies, and individuals positive for Hp were excluded in 24 of the studies. In 10 studies, Hp-positive subjects (between 10 and 20%) were included. In 21 of the studies, Hp status was not tested and not used as an inclusion or exclusion criterion.

In Table 1, the mean intragastric pH measured over 24 h is listed for different doses of a PPI. Data are presented for single-dose studies and multiple-dose studies (Table 1), and for healthy individuals or GERD patients, separately. The mean pH and the standard deviations are presented weighted according to study sample sizes.

For omeprazole, data on 10, 20, and 40 mg daily doses were found for single- and multiple-dosing conditions. GERD patients had lower mean 24-h pH values than healthy subjects, and multiple dosing increased pH significantly compared to single doses ($P < 0.001$ for both factors, ANOVA). Even after a relatively small dose of 20 mg, mean gastric pH was significantly higher (3.5 in healthy [21–23] and 3.6 in patients [1, 3, 24, 25]) after multiple compared to single dosages (1.8 in healthy [2, 26–28]).

For esomeprazole, data on dosages of 20, 40, and 80 mg were identified. Most studies were performed in patients with GERD, and these patients had a trend towards lower mean pH compared to healthy individuals after 40 mg esomeprazole (4.4 vs. 4.8, $P = 0.07$, based on seven studies [1, 3, 24, 29–31, 32]).

For pantoprazole, data on 10, 20, 40, 60, 80, and 120 mg dosages were found. For the 40 mg dose, data on both patients with GERD as well as healthy volunteers were

Table 1 Mean intragastric pH±standard deviation over 24 h after single doses and multiple doses of proton-pump inhibitors (PPIs)

Substance	Dose	Participants	pH (<i>n</i> of individuals)	References
Single-dose studies				
Omeprazole	10 mg	V	1.4 (27)	[58]
	20 mg	V	1.8 (73)	[2, 26–28]
	40 mg	V	3.8 (14)	[59]
Esomeprazole	20 mg	V	3.2±0.6 (48)	[60, 61]
	40 mg	V	3.6±0.8 (101)	[29, 60–62]
	40 mg	G	3.6±1.1 (94)	[3]
Pantoprazole	40 mg	V	2.9(132)	[2, 26, 27, 38, 63, 64]
		G	2.9±0.9 (60)	[3, 65]
Lansoprazole	15 mg	V	3.1±0.5 (65)	[36]
	30 mg	V	3.4±0.5 (203)	[2, 36, 38, 40, 66]
Rabeprazole		G	3.2±0.6 (30)	[3]
	5 mg	HP	3.2±0.3 (19)	[19]
	10 mg	V	3.1±0.6 (120)	[36, 58, 61]
		HP	3.9±0.3 (19)	[19]
	20 mg	V	3.5±0.6 (218)	[2, 28, 36, 60, 61, 65, 67]
		G	3.3±1.1 (77)	[3, 53, 68]
	40 mg	HP	4.6±0.3 (19)	[19]
	HP	5.3±0.3 (19)	[19]	
Multiple-dose studies				
Omeprazole	10 mg	V	1.9 (27)	[58]
	20 mg	V	3.5±1.0 (122)	[21–23]
		G	3.6±0.1 (111)	[1, 3, 24, 25]
		HP	5.5 (18)	[20]
Esomeprazole	40 mg	V	4.6±1.4 (76)	[22, 59, 69–71]
	20 mg	V	4.2±0.6 (48)	[60, 61]
		G	4.1 (36)	[24]
	40 mg	V	4.8±0.7 (116)	[29–31]
		G	4.4±0.8 (199)	[1, 3, 24, 32]
	80 mg	V	6.4 (30)	[72]
Pantoprazole		G	5.1 (35)	[32]
	10 mg	V	2.9±1.4 (36)	[73]
	20 mg	V	3.2±1.7 (51)	[73–75]
	40 mg	V	3.5±1.4 (195)	[26, 27, 38, 63, 64, 73, 74–78]
		G	3.6±0.9 (75)	[1, 3, 79]
	60 mg	V	3.5 (14)	[76]
	80 mg	V	4.3 (61)	[72, 74, 75, 78]
		G	4.7 (18)	[80]
	120 mg	V	3.6 (15)	[78]
	Lansoprazole	10 mg	V	4.3 (4)
15 mg		V	3.9±0.6 (94)	[21, 36]
20 mg		V	3.5 (4)	[81]
30 mg		V	4.1±0.7 (298)	[21, 31, 34, 36–38, 40, 41, 71, 81]
		G	3.7±2.2 (100)	[1, 3, 32]
		HP	5.4 (18)	[20]
60 mg		V	4.7 (54)	[21, 37, 71, 81]
80 mg		V	4.4±3.6 (35)	[32]
90 mg		V	5.1 (35)	[37, 71]
120 mg		V	5.0 (35)	[37, 71]
180 mg		V	5.1 (16)	[37]
Rabeprazole		5 mg	HP	4.9±0.2 (19)
	10 mg	V	4.1±0.6 (143)	[36, 58, 61, 82]
		HP	5.7±0.3 (19)	[19]
	20 mg	V	4.5±0.5 (197)	[28, 31, 36, 60, 61, 67, 82]
		G	3.3±1.1 (77)	[3, 53, 68]
		HP	6.2±0.3 (19)	[19]
	40 mg	V	4.9 (24)	[82, 83]
		HP	6.4±0.2 (19)	[19]

Means were calculated as the sample-size-weighted means of the individual studies, the number following the ± symbol is the standard deviation referring to between-subject variability and calculated as given in the “Methods” section. *Numbers in parentheses* are the total number of subjects analysed in the respective group. If only one study was available, the standard deviation within the single study is given *V* Healthy volunteers, *G* GERD, *HP Helicobacter-positive* healthy individuals

available ($n=195$ for healthy individuals and $n=75$ for GERD patients). No difference in mean pH was detected between the two groups (mean pH 3.5 vs. 3.6).

Data on lansoprazole were identified with daily doses of 10, 15, 20, 30, 60, 90, 120, and 180 mg. Most data were available for the 30 mg dose (multiple dosing), and significant differences were observed for mean 24-h pH in healthy individuals versus GERD patients (5.1 versus 4.8, $P=0.004$ for 30 mg dose, *t*-test) [1, 3, 21, 23, 31–41].

Data on single and multiple dosages of 5, 10, 20, and 40 mg of rabeprazole were available. One study in 18 Hp-positive healthy individuals was included but analyzed separately. Hp-positive individuals had higher mean pH values at the given rabeprazole dosages compared to healthy individuals ($P=0.03$ for multiple 20 mg doses). GERD patients had lower mean pH compared to healthy volunteers (mean pH at 20 mg multiple dosages was 3.3 for GERD patients and 4.5 for healthy individuals, $P=0.004$).

In addition to the mean pH over time, in many clinical studies the percentage of time with $\text{pH}>4$ was used as a surrogate parameter for the efficacy of PPIs in treatment of GERD. The data obtained for percentage of time (for 24 h) with $\text{pH}>4$ are shown in Table 2. Data are given as sample-size-weighted mean and standard deviation in patients and healthy volunteers for single and multiple doses. As can be seen from the single-dose data, one single PPI dose is not enough to obtain a $\text{pH}>4$ for 50% of the time or longer but with multiple dosing over several days, the aim to increase pH above 4 was achieved for at least 70–80% with higher dosages. There were no significant differences in mean percentage of time with $\text{pH}>4$ between patients with GERD and healthy individuals for any of the PPIs.

In Fig. 2, the reported percentages of time with $\text{pH}>4$ for each PPI dose are depicted for GERD patients and healthy individuals. The values did not differ very much between GERD patients and healthy individuals, which was in keeping with similar results in several individual studies.

Population pharmacokinetic analysis of the entire dataset identified no interindividual variation for E_{max} , the maximum possible increase in pH, and no discernable differences in E_{max} among the five PPIs. However, Hp-infected patients formed a distinct group with a separate estimator for ED_{50} . The estimated ED_{50} values and the estimated doses required to achieve a mean pH of 4 or less for each PPI are summarized in Table 3. Estimations were only done for multiple-dose conditions, since single doses did not allow the therapeutic goals to be met.

The estimated relationships between dose and mean 24-h pH are depicted in Fig. 3 for each PPI and separately for healthy volunteers, GERD patients, and Hp patients to the extent that the respective dose has been studied.

Based on the mean 24-h gastric pH, the relative potencies of the five PPIs compared to omeprazole were

0.23, 0.90, 1.00, 1.60, and 1.82 for pantoprazole, lansoprazole, omeprazole, esomeprazole, and rabeprazole, respectively. Compared with healthy volunteers, patients with GERD needed a 1.9-fold higher dose and Hp-positive individuals needed only 15% of the dose to achieve a given increase in mean 24-h intragastric pH (Table 3). There were not sufficient data to find significant differences among the three subgroups (healthy, healthy with Hp, and patients with GERD) concerning the basal pH values prior to PPI treatment and the maximum achievable pH (E_{max}).

Discussion

The present analysis provides estimates of the relative potencies of PPIs based on peer-reviewed published data on gastric pH effects. This information provides a rationale for mutual replacement of PPIs in clinical practice and for scientific comparisons of studies with different PPIs. Intra-gastric pH measurements, particularly expressed as percent time with $\text{pH}>4$ (Table 3), are established biomarkers of the therapeutic efficacy of PPIs [30]. Maintenance of $\text{pH}>4$ is an important objective in management of GERD: when the pH of the acid reflux rate falls below 4, patients may experience mucosal injury in the esophagus [42, 43].

Confounding factors and other limitations

There are several confounding variables leading to variability among the individuals within the studies and to variability among the studies themselves, and probably not everything but only the most important factors should be considered in our meta-analysis. Generally, for our analyses we would have wished that for each of the five PPIs, the dose-response relationship would have been tested in the dose range between 5 and 200 mg under the same clinical study conditions in subjects well characterized for Hp status and disease status. This was apparently not the case and this of course limits the reliability of the results of our meta-analysis. Nevertheless, our comprehensive analysis may put a new light on the relative potencies of the PPIs, which cannot be obtained by *in vitro* measurements (since these would, for instance, not reflect differences in pharmacokinetics) and which cannot be obtained from studies focusing on clinical endpoints, since these studies are less precise and have not been performed over a sufficient range of dosages.

Because of different basic pH and different responses to PPIs, we stratified the data into studies in healthy individuals, GERD patients, and studies exclusively performed in Hp-positive individuals. We did not mix up studies performed in Asian individuals with Caucasian individuals because of the differences in body mass index

Table 2 Mean percent duration of time with intragastric pH>4 after single doses and multiple doses of proton-pump inhibitors (PPIs)

Substance	Dose	Participants	Mean percent time with pH<4	References
Single-dose studies				
Omeprazole	10 mg	V	10.8 (27)	[58]
	20 mg	V	30.4 (57)	[2, 26–28]
Esomeprazole	20 mg	V	32.5±9.2 (48)	[60, 61]
	40 mg	V	43.1±17.8 (101)	[29, 61, 62, 65]
Pantoprazole	40 mg	G	43.9±18.8 (94)	[3]
		V	29.2±18.0 (149)	[2, 27, 34, 38, 64]
Lansoprazole	15 mg	V	28.1±10 (65)	[35]
	30 mg	V	39.1±12.8 (253)	[2, 21, 34, 35, 38, 40, 66]
Rabeprazole	10 mg	G	33.4±14.0 (30)	[3]
		V	29.8±13.2 (120)	[36, 58, 61]
		V	42.8±15.9 (177)	[2, 28, 36, 60, 61, 65, 67]
	20 mg	G	34.9±15.2 (57)	[3, 53, 68]
Multiple-dose studies				
Omeprazole	10 mg	V	18.3 (27)	[58]
	20 mg	V	48.7±20.5 (126)	[21–23, 27, 28, 35, 70]
		G	45.5±19.7 (106)	[1, 3, 24]
	40 mg	V	63.2±17.3 (83)	[22, 23, 70, 84]
Esomeprazole	20 mg	G	53.4±(49)	[85]
		V	56.3±7.4 (48)	[60, 61]
	40 mg	G	53.0 (36)	[24]
		V	64.6±15.2 (212)	[29–31, 86, 87]
Pantoprazole	80 mg	G	62.5±18.9 (199)	[1, 3, 24, 32]
		V	84.9 (59)	[72, 86]
	10 mg	G	81.0±24.1 (35)	[32]
		V	34.9±21.4 (36)	[73]
Lansoprazole	20 mg	V	42.4±23.6 (35)	[73]
	40 mg	V	53.6±19.8 (269)	[27, 38, 63, 64, 73, 87, 88]
	80 mg	G	43.3±16.5 (64)	[1, 3]
		V	70.8 (30)	[72]
Rabeprazole	15 mg	G	56.2 (18)	[80]
		V	45.9±14.3 (123)	[21, 35, 36, 39]
	30 mg	V	55.1±14.4 (360)	[21, 23, 31, 33–41]
		G	48.0±15.5 (100)	[1, 3, 32]
	45 mg	V	58 (12)	[39]
	60 mg	V	64.7 (76)	[33, 37, 39, 89]
Rabeprazole	90 mg	G	65.6±18.1 (35)	[32]
		V	87 (16)	[37]
	120 mg	V	83 (16)	[37]
		V	51.2±13.1 (143)	[36, 58, 61, 82]
20 mg	V	57.7±14.2 (197)	[28, 31, 36, 60, 61, 67, 82]	
	G	50.8±15.3 (77)	[1, 3, 53, 90]	
	40 mg	V	70.8 (24)	[82]

Mean duration of time with pH>4 is depicted as sample-size-weighted mean value of the means of the different studies. The number following the ± symbol is the standard deviation referring to between-subject variability and calculated as given in the “Methods” section. Numbers in parentheses are the total number of subjects analyzed in the respective group. Standard deviation of the means of the different studies is given if more than one study was available. Otherwise, the standard deviation within the single study is given
 V Healthy volunteers,
 G GERD

and differences in metabolizing activity due to genetics. In Asian populations, about 20% are poor metabolizers of drugs metabolized by CYP2C19 including all PPIs [44].

The activity and the genotype of the cytochrome P450 enzyme CYP2C19, which determines to a large extent the pharmacokinetics of all five tested PPIs, was not directly considered in this analysis because in the majority of studies in Caucasians either the CYP2C19 genotype was not analyzed or at least was not published. While there are a

lot of data showing evidence that the CYP2C19 genotype has a tremendous impact on pharmacokinetics of PPIs, only a few studies in Caucasians assessed the influence of the CYP2C19 genotype on mean 24-h intragastric pH. Thus, the CYP2C19 genotype could not be integrated into our model. However, since the CYP2C19 genotype influences drug metabolism, differences between the metabolizer groups on mean pH can be estimated from the differences in drug exposure. In Table 4, the influence of the CYP2C19

Fig. 2 The upper figure (a) shows the percentage of 24-h time at which gastric pH was above 4.0 in relation to the dose of the PPI. Only data from multiple dosing studies are shown. The lower figure (b) shows the mean 24-h gastric pH measurements from all multiple dose studies analyzed in the present review. These data are the basis of the nonlinear regression analysis presented in Fig. 3 and Table 3. Data measured in healthy volunteers are shown as *circles*, data from patients with GERD are shown as *triangles* and data from *Helicobacter pylori* positive healthy volunteers are shown as *squares*




Table 3 Parameters reflecting proton-pump-inhibitor effects on 24-h gastric pH according to an integrated population pharmacokinetic model


	ED ₅₀ (mg/day) ^a			Dose to achieve a mean 24-h pH of 4 (mg/day)		
	Healthy	GERD	Hp-infected	Healthy	GERD	Hp-infected
Pantoprazole	239 (185–308)	445 (344–574)	No data	89.2	166	No data
Omeprazole	54.2 (42.0–69.0)	101 (78–130)	8.0 (6.2–10.3)	20.2	37.7	3.0
Rabeprazole	29.8 (23.1–38.4)	55.6 (43.1–71.7)	4.4 (3.4–5.6)	11.1	20.7	1.6
Lansoprazole	60.5 (46.9–78.0)	112 (86.8–144)	8.88 (6.9–11.4)	22.6	41.8	3.3
Esomeprazole	33.9 (26.3–43.7)	63.3 (49.1–81.7)	No data	12.6	23.6	No data
For all drugs						
Basal pH ^b	3.06	3.06	3.06			
E _{max} (pH) ^c	3.46	3.46	3.46			

^a Numbers are means ± standard deviation calculated from the exponential error model

^b It is likely that basal pH differed between healthy volunteers with and without *Helicobacter pylori* (Hp) infection and patients with GERD, however, it was not possible with the data collected in this meta-analysis to find significant differences among the three groups

^c According to the model used (see “Methods” section) this must be added to the basal pH for the maximum pH achieved

Fig. 3 Predicted mean 24-h pH values in relation to the dose of the PPIs. Only predictions for those dose ranges are shown which have been studied as given in Tables 1 and 2. The curves depicted are for healthy volunteers (*circles*), patients with GERD (*triangles*) and H.p. positive healthy volunteers (*squares*). The analysis yielding these mean estimates is described in the “Methods” section



genotype is expressed as a dose factor that can be derived from pharmacokinetic data on clearance or AUC (data taken from [10, 11, 45–50]) and transformed by using the methods described earlier [51, 52]. Thus, the effects of genotype on mean pH can be extrapolated when calculating the genotype-specific dose by applying the dose correction factor to the dose given to the patients.

One confounding factor that could not be optimally considered was Hp status. In about half of the studies included, Hp was not tested, and in some studies, a small fraction of Hp-positive individuals was included. Since the percentage of Hp-positive individuals in the normal

population is about 10–20% [53], and because in those studies including Hp-positive individuals, this fraction was typically 16–20%, we decided to include such studies since this fraction of potentially Hp-positive individuals would not drastically alter the mean pH of the whole group. In addition, it also reflects the clinical situation in which GERD patients treated with PPIs are usually not tested for Hp.

We further neglected the time of dosing during the day and the dose splitting, and only referred to the daily dosages. Of course, dose splitting has an effect on pharmacokinetics and also intragastric pH, but since in clinical practice, single daily doses are much more practicable and often the exact time of drug intake is not known, we did not account for the influences of dose splitting during the day.

Table 4 Dose correction factors for *CYP2C19* poor and intermediate metabolizers. Data are from [10, 11, 45–50, 91, 92]

	Extensive metabolizers: <i>CYP2C19</i> *1/*1	Intermediate metabolizers: <i>CYP2C9</i> *1/*2	Poor metabolizers: <i>CYP2C19</i> *2/*2
Omeprazole	1	0.33	0.12
Rabeprazole	1	0.58	0.37
Lansoprazole	1	0.59	0.24
Pantoprazole	1	0.23 ^a	0.16
Esomeprazole	1	0.77	0.32

Differences are expressed as percent oral clearance or percent 1/AUC compared to *CYP2C19**1/*1 (normal metabolizer) genotype. Dose correction factors can be calculated by multiplying the factor by a common dose in order to obtain the dosage necessary to obtain similar pharmacokinetic parameters in *CYP2C19* poor metabolizers. In contrast, drug exposure can be calculated by dividing a given dose by the dose correction factor

^aData on *CYP2C19**1/*2 and pantoprazole were only from one study [92]

Dose equivalents according to the literature

Different national and international guidelines for dosing of PPIs exist. The WHO Collaborating Centre for Drug Statistics Methodology (<http://www.whocc.no/atcddd/>) proposes doses of 20 mg omeprazole, 30 mg esomeprazole, 30 mg lansoprazole, 40 mg pantoprazole, and 20 mg rabeprazole to be equivalent for the treatment of GERD. From this recommendation, it is not at all evident why a higher dose of esomeprazole is recommended compared to that of racemic omeprazole. According to Table 3 and other analyses [54], it is well documented that 30 mg omeprazole would rather correspond to 20 mg esomeprazole.

The Canadian Association of Gastroenterology recommends 20 mg omeprazole to be equivalent to 40 mg esomeprazole, 30 mg lansoprazole, 40 mg pantoprazole,

and 20 mg rabeprazole for acute treatment of GERD [55]. Again, according to the clinical data, esomeprazole does not seem to be less potent than omeprazole [54], thus, the basis of the recommendation of twice the esomeprazole dose relative to omeprazole may be based on studies showing a particular value of 40 mg esomeprazole dose [24], but apparently not on comparison of pharmacologically defined potencies or efficacies.

The FDA provides dosages for the PPIs for approved indications and for treatment of GERD (<http://www.pbm.va.gov/reviews/ppiabbreviatedreview.pdf>). Different dosages are given for symptom relief, to maintain symptom control of nonerosive GERD, and to heal or maintain symptom relief of erosive or ulcerative esophagitis. The omeprazole equivalents for symptom relief of GERD are given by the FDA as 1 for esomeprazole, 0.75 for lansoprazole, 2 for pantoprazole, and 1 for rabeprazole. The comparative doses of PPIs according to the FDA were based on relative efficacies based on subjective or objective measures of response to treatment reported in double-blind, randomized controlled trials or systematic reviews in patients with gastrointestinal acid-related disorders.

One meta-analysis of Caro et al. assessed the endoscopic healing of erosive esophagitis [56]. The dosages for obtaining similar 8-week overall healing rates were omeprazole 20 mg/day, lansoprazole 30 mg/day, rabeprazole 20 mg/day, and pantoprazole 40 mg/day. These estimates are in a similar range to our findings although the dosage of omeprazole would be slightly higher according to our data.

Another review comparing pharmacokinetics, acid suppression, and efficacy of PPIs concluded from comparative studies of acid suppression that lansoprazole and pantoprazole have a potency similar to that of omeprazole, whereas rabeprazole had a greater potency than omeprazole on a per-milligram basis [57]. However, this was not a systematic analysis of all available data on acid suppression at different PPI doses, and therefore could only provide a rough estimate of dose equivalents.

In summary, there are several guidelines for the different PPIs with considerable differences in the dosage, leading to a confusing picture concerning comparative efficacy of PPIs. In none of the compilations are dose recommendations comprehensive, and often individual selected studies appeared to be the basis of the recommendations. This lack of true comparative efficacy data may be in part due to the comparison of the limited number of fixed doses, which were not equivalent. In this context, using relevant data published in an accessible way and under peer-reviewed conditions, the present analysis attempted to derive dose equivalents based on the effect on gastric pH, which is known to be representative of the clinical efficacy. Of course, our meta-analysis based on surrogate markers is not intended to change daily clinical practice in a typical

patient. The equivalence doses assessed provide a rationale for the appropriate dose selection for a patient when switching to a different PPI and for calculating the cost-effectiveness of individual PPIs.

Acknowledgements Part of the cost for compilation of this analysis was provided by an educational grant from Eisai-Deutschland GmbH.

Conflict of interest None of the authors has any conflict of interest that might potentially bias this work.

References

1. Miner P Jr, Katz PO, Chen Y, Sostek M (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. *Am J Gastroenterol* 98:2616–2620
2. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL (2003) Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. *Aliment Pharmacol Ther* 17:1507–1514
3. Rohss K, Lind T, Wilder-Smith C (2004) Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. *Eur J Clin Pharmacol* 60:531–539
4. Klok RM, Postma MJ, van Hout BA, Brouwers JR (2003) Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. *Aliment Pharmacol Ther* 17:1237–1245
5. Hellstrom PM, Vitols S (2004) The choice of proton pump inhibitor: does it matter? *Basic Clin Pharmacol Toxicol* 94:106–111
6. Katz PO (2006) Review article: intragastric and oesophageal pH monitoring in patients with gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 23(Suppl 1):3–11
7. Bell NJ, Hunt RH (1992) Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. *Gut* 33:118–124
8. Burget DW, Chiverton SG, Hunt RH (1990) Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. *Gastroenterology* 99:345–351
9. Howden CW, Hunt RH (1990) The relationship between suppression of acidity and gastric ulcer healing rates. *Aliment Pharmacol Ther* 4:25–33
10. Klotz U (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. *Int J Clin Pharmacol Ther* 44:297–302
11. Klotz U, Schwab M, Treiber G (2004) CYP2C19 polymorphism and proton pump inhibitors. *Basic Clin Pharmacol Toxicol* 95:2–8
12. Verdu EF, Armstrong D, Fraser R, Viani F, Idstrom JP, Cederberg C, Blum AL (1995) Effect of *Helicobacter pylori* status on intragastric pH during treatment with omeprazole. *Gut* 36:539–543
13. Gillen D, Wirz AA, Neithercut WD, Ardill JE, McColl KE (1999) *Helicobacter pylori* infection potentiates the inhibition of gastric acid secretion by omeprazole. *Gut* 44:468–475
14. Giral A, Celikel CA, Ozdogan O, Tozun N, Ulusoy NB, Kalayci C (2005) Impact of *Helicobacter pylori* eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. *J Gastroenterol Hepatol* 20:1886–1891
15. Blonski WC, Shih GL, Brensinger CM, Katzka DA, Metz DC (2006) Analysis of the acidity index and integrated intragastric

- acidity in 645 patients presenting with gastroesophageal reflux disease symptoms. *Scand J Gastroenterol* 41:382–389
16. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishizaki T (2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. *Drug Metab Pharmacokinet* 20:153–167
 17. Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. *Clin Pharmacokinet* 41:913–958
 18. Spechler SJ, Jain SK, Tendler DA, Parker RA (2002) Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 16:1795–1800
 19. Ohning GV, Barbuti RC, Kovacs TO, Sytnik B, Humphries TJ, Walsh JH (2000) Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 14:701–708
 20. Verdu EF, Fraser R, Armstrong D, Blum AL (1994) Effects of omeprazole and lansoprazole on 24-hour intragastric pH in *Helicobacter pylori*-positive volunteers. *Scand J Gastroenterol* 29:1065–1069
 21. Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH (1997) The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. *Clin Ther* 19:1013–1023
 22. Delchier JC, Benamouzig R, Stanescu L, Ropert A, Vallot T, Wirquin V, Roudot F, Lamarque D, Hamelin B (1997) Twenty-four-hour intragastric acidity and plasma gastrin during 3-month treatment with omeprazole in healthy subjects. *Aliment Pharmacol Ther* 11:747–753
 23. Katz PO, Xue S, Castell DO (2001) Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. *Aliment Pharmacol Ther* 15:647–652
 24. Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Rohss K (2000) Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 14:861–867
 25. Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R (2000) Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. *Gastroenterology* 119:670–676
 26. Hartmann M, Theiss U, Huber R, Luhmann R, Bliesath H, Wurst W, Lucker PW (1996) Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. *Aliment Pharmacol Ther* 10:359–366
 27. Geus WP, Mathot RA, Mulder PG, Lamers CB (2000) Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in *Helicobacter pylori*-negative subjects. *Aliment Pharmacol Ther* 14:1057–1064
 28. Williams MP, Sercombe J, Hamilton MI, Pounder RE (1998) A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. *Aliment Pharmacol Ther* 12:1079–1089
 29. Hammer J, Schmidt B (2004) Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. *Aliment Pharmacol Ther* 19:1105–1110
 30. Hunt RH (1995) The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 9(Suppl 1):3–7
 31. Wilder-Smith CH, Rohss K, Nilsson-Pieschl C, Junghard O, Nyman L (2003) Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. *Digestion* 68:184–188
 32. Johnson DA, Stacy T, Ryan M, Wootton T, Willis J, Hornbuckle K, Brooks W, Doviak M (2005) A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 22:129–134
 33. Dammann HG, von zur Muhlen A, Balks HJ, Damaschke A, Steinhoff J, Hennig U, Schwarz JA, Fuchs W (1993) The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers. *Aliment Pharmacol Ther* 7:191–196
 34. Freston J, Chiu YL, Pan WJ, Lukasik N, Taubel J (2001) Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. *Am J Gastroenterol* 96:2058–2065
 35. Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL (1997) The effects of oral doses of lansoprazole and omeprazole on gastric pH. *J Clin Gastroenterol* 24:65–70
 36. Tolman KG, Taubel J, Warrington S, Chiu YL, Pilmer BL, Pan WJ (2006) Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. *Clin Drug Investig* 26:21–28
 37. Blum RA, Hunt RH, Kidd SL, Shi H, Jennings DE, Greski-Rose PA (1998) Dose-response relationship of lansoprazole to gastric acid antisecretory effects. *Aliment Pharmacol Ther* 12:321–327
 38. Florent C, Forestier S (1997) Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30 mg and pantoprazole 40 mg. *Eur J Gastroenterol Hepatol* 9:195–200
 39. Harder H, Teyssen S, Stephan F, Pfutzer R, Kiel G, Fuchs W, Singer MV (1999) Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects. *Scand J Gastroenterol* 34:551–561
 40. Huang JQ, Goldwater DR, Thomson AB, Appelman SA, Sridhar S, James CF, Chiu YL, Pilmer BL, Keith RG, Hunt RH (2002) Acid suppression in healthy subjects following lansoprazole or pantoprazole. *Aliment Pharmacol Ther* 16:425–433
 41. Bell N, Karol MD, Sachs G, Greski-Rose P, Jennings DE, Hunt RH (2001) Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. *Aliment Pharmacol Ther* 15:105–113
 42. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. *Digestion* 51(Suppl 1):59–67
 43. Armstrong D (2004) Review article: gastric pH - the most relevant predictor of benefit in reflux disease? *Aliment Pharmacol Ther* 20(Suppl 5):19–26, discussion 38–39
 44. Wedlund PJ (2000) The CYP2C19 enzyme polymorphism. *Pharmacology* 61:174–183
 45. Lin CJ, Yang JC, Uang YS, Chern HD, Wang TH (2003) Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. *Pharmacotherapy* 23:711–719
 46. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T (2001) Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. *Aliment Pharmacol Ther* 15:1929–1937
 47. Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T (2001) Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. *Aliment Pharmacol Ther* 15:793–803
 48. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M,

- Okumura K (2001) CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. *Pharm Res* 18:721–727
49. Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K, Ishizaki T (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. *Eur J Clin Pharmacol* 57:485–492
 50. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. *Clin Pharmacol Ther* 76:290–301
 51. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. *Mol Psychiatry* 9:442–473
 52. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. *Acta Psychiatr Scand* 104:173–192
 53. Robinson M, Maton PN, Rodriguez S, Greenwood B, Humphries TJ (1997) Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 11:973–980
 54. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM (2006) Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. *Clin Gastroenterol Hepatol* 4:1452–1458
 55. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, Hollingworth R, Hunt RH, Kahrlas PJ, Mayrand S, Moayyedi P, Paterson WG, Sadowski D, van Zanten SJ (2005) Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. *Can J Gastroenterol* 19:15–35
 56. Caro JJ, Salas M, Ward A (2001) Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. *Clin Ther* 23:998–1017
 57. Stedman CA, Barclay ML (2000) Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. *Aliment Pharmacol Ther* 14:963–978
 58. Bruley des Varannes S, Gharib H, Bicheler V, Bost R, Bonaz B, Stanescu L, Delchier JC, Bonnot-Marlier S (2004) Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. *Aliment Pharmacol Ther* 20:899–907
 59. Hurlimann S, Abbuhl B, Inauen W, Halter F (1994) Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. *Aliment Pharmacol Ther* 8:193–201
 60. Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N (2002) Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. *Aliment Pharmacol Ther* 16:1301–1307
 61. Norris V, Baisley K, Dunn K, Warrington S, Morocutti A (2007) Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers. *Aliment Pharmacol Ther* 25:501–510
 62. Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S, Vavasseur F, Taccoen A, Fiorentini P, Homerin M (2005) A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. *Aliment Pharmacol Ther* 21:575–582
 63. Hartmann M, Ehrlich A, Fuder H, Luhmann R, Emeklibas S, Timmer W, Wurst W, Lucker PW (1998) Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. *Aliment Pharmacol Ther* 12:1027–1032
 64. Huang JQ, Hunt RH (2001) Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. *Best Pract Res Clin Gastroenterol* 15:355–370
 65. Warrington S, Baisley K, Dunn K, Boyce M, Morocutti A (2006) Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. *Eur J Clin Pharmacol* 62:685–691
 66. Doan TT, Wang Q, Griffin JS, Lukasik NL, O'Dea RF, Pan WJ (2001) Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. *Am J Health Syst Pharm* 58:1512–1519
 67. Armstrong D, James C, Camacho F, Chen Y, Horbay GL, Teixeira B, Husein-Bhabha FA (2007) Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. *Aliment Pharmacol Ther* 25:185–196
 68. Warrington S, Baisley K, Lee D, Lomax K, Delemos B, Boyce M, Morocutti A (2007) Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. *Aliment Pharmacol Ther* 25:511–517
 69. Prichard PJ, Yeomans ND, Mihaly GW, Jones DB, Buckle PJ, Smallwood RA, Louis WJ (1985) Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. *Gastroenterology* 88:64–69
 70. Houben GM, Hooi J, Hameeteman W, Stockbrugger RW (1995) Twenty-four-hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo. *Aliment Pharmacol Ther* 9:649–654
 71. Timmer W, Ripke H, Kleist P, Ehrlich A, Wieckhorst G, Lucker PW, Fuder H (1995) Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. *Methods Find Exp Clin Pharmacol* 17:489–495
 72. Miehke S, Madisch A, Kirsch C, Lindner F, Kuhlisch E, Laass M, Knoth H, Morgner A, Labenz J (2005) Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily—a randomized, two-way crossover study. *Aliment Pharmacol Ther* 21:963–967
 73. Tutuian R, Katz PO, Bochenek W, Castell DO (2002) Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. *Aliment Pharmacol Ther* 16:829–836
 74. Londong W (1994) Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. *Aliment Pharmacol Ther* 8(Suppl 1): 39–46
 75. Reill L, Erhardt F, Fischer R, Huber R, Londong W (1993) Dose-response of pantoprazole 20, 40 and 80 mg on 24-hour intragastric pH and serum gastrin in man (abstract). *Gut* 34(suppl 4):F251
 76. Hannan A, Weil J, Broom C, Walt RP (1992) Effects of oral pantoprazole on 24-hour intragastric acidity and plasma gastrin profiles. *Aliment Pharmacol Ther* 6:373–380
 77. Ehrlich A, Lucker PW, Wiedemann A, Sander P, Huber R, Mascher H (1999) Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. *Methods Find Exp Clin Pharmacol* 21:47–51
 78. Koop H, Kuly S, Flug M, Eissele R, Monnikes H, Rose K, Luhmann R, Schneider A, Fischer R, Arnold R (1996) Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. *Eur J Gastroenterol Hepatol* 8:915–918
 79. Armbrrecht U, Abucar A, Hameeteman W, Schneider A, Stockbrugger RW (1997) Treatment of reflux oesophagitis of

- moderate and severe grade with ranitidine or pantoprazole-comparison of 24-hour intragastric and oesophageal pH. *Aliment Pharmacol Ther* 11:959–965
80. Castell D, Bagin R, Goldlust B, Major J, Hepburn B (2005) Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 21:1467–474
81. Sanders SW, Tolman KG, Greski PA, Jennings DE, Hoyos PA, Page JG (1992) The effects of lansoprazole, a new H⁺,K⁺-ATPase inhibitor, on gastric pH and serum gastrin. *Aliment Pharmacol Ther* 6:359–372
82. Williams MP, Blanshard C, Millson C, Sercombe J, Pounder RE (2000) A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. *Aliment Pharmacol Ther* 14:691–699
83. Eisai Corporation (2001) Clinical investigator's brochure rabeprazole sodium (E3810, LY307640 sodium). Eisai, Teaneck, NJ
84. Hatlebakk JG, Katz PO, Kuo B, Castell DO (1998) Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. *Aliment Pharmacol Ther* 12:1235–1240
85. Katz PO, Koch FK, Ballard ED, Bagin RG, Gautille TC, Checani GC, Hogan DL, Pratha VS (2007) Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. *Aliment Pharmacol Ther* 25:197–205
86. Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB (2004) Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. *Aliment Pharmacol Ther* 20:399–406
87. Miner PB Jr, Tutuian R, Castell DO, Liu S, Sostek MB (2006) Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers. *Clin Ther* 28:725–733
88. Goldstein JL, Miner PB Jr, Schlesinger PK, Liu S, Silberg DG (2006) Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. *Aliment Pharmacol Ther* 23:1189–1196
89. Katz PO, Hatlebakk JG, Castell DO (2000) Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. *Aliment Pharmacol Ther* 14:709–714
90. Toruner M, Bektas M, Cetinkaya H, Soykan I, Ozden A (2004) The effect of rabeprazole alone or in combination with H₂ receptor blocker on intragastric pH: a pilot study. *Turk J Gastroenterol* 15:225–228
91. Lou HY, Chang CC, Sheu MT, Chen YC, Ho HO (2008) Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. *Eur J Clin Pharmacol*. doi:10.1007/s00228-008-0552-0
92. Hunfeld NG, Mathot RA, Touw DJ, van Schaik RH, Mulder PG, Franck PF, Kuipers EJ, Geus WP (2008) Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. *Br J Clin Pharmacol* 65:752–760
93. Clarke M (2000) The QUORUM statement. *Lancet* 355:756–757